Aflac Incorporated

Aflac Incorporated (AFL) Market Cap

Aflac Incorporated has a market capitalization of $58.66B.

Price: $115.24

-3.00 (-2.54%)

Market Cap: 58.66B

NYSE · time unavailable

CEO: Daniel Paul Amos

Sector: Financial Services

Industry: Insurance - Life

IPO Date: 1980-03-17

Website: https://www.aflac.com

Aflac Incorporated (AFL) - Company Information

Market Cap: 58.66B|Sector: Financial Services

Company Profile

Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. It operates through two segments, Aflac Japan and Aflac U.S. The Aflac Japan segment offers cancer, medical, nursing care income support, GIFT, and whole and term life insurance products, as well as WAYS and child endowment plans under saving type insurance products in Japan. The Aflac U.S. segment provides cancer, accident, short-term disability, critical illness, hospital indemnity, dental, vision, long-term care and disability, and term and whole life insurance products in the United States. It sells its products through sales associates, brokers, independent corporate agencies, individual agencies, and affiliated corporate agencies. The company was founded in 1955 and is based in Columbus, Georgia.

Analyst Sentiment

51%
Hold

From 14 Active Polls

1Y Forecast: $115.17

▼ -0.1% Potential Upside

Consensus Target Metrics

Low Bound

$99

Median

$117

High Bound

$130

Average

$115

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$115.17
▼ -0.06% Upside
Low Target
$99.00
-14% Risk
Median Target
$116.50
1% Mid
High Target
$130.00
13% Max
Consensus
Hold
9 / 32 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024
Market Cap ($M)58,65556,28958,44959,20756,59960,56657,70962,37350,281
Enterprise Value ($M)61,17558,80960,61361,20758,56763,08658,97864,73951,676
Price to Earnings Ratio (P/E)12.7513.8110.609.0323.62522.127.59-167.677.16
Price/Earnings-to-Growth Ratio (PEG)4.930.661.070.09
Price to Sales Ratio (P/S)3.2213.0411.9412.3513.4217.5410.5020.559.75
Price to Book Ratio (P/B)2.632.511.982.062.082.302.212.511.93
Price to Free Cash Flow Ratio (P/FCF)19.9958.15185.5547.29141.85102.83173.3049.11197.18
Enterprise Value to Sales (EV/Sales)13.6312.3812.7713.8918.2710.7321.3310.02
Enterprise Value to EBITDA (EV/EBITDA)9.1845.7732.7322.6271.25435.0827.62703.6925.59
Debt to Equity Ratio0.380.350.290.310.330.290.290.320.29

AFL Growth Runway Model

Standard long term linear growth fade

Multi-Stage Discounted Cash Flow Sandbox

Market Price$115.24
Intrinsic Value$115.77
Market Alignment
Undervalued by 0.5%relative to calculated intrinsic value
9.00%
Exp: -7%-7%
i

Growth runway slowdown

This value provides a time window for the growth rate to decline beyond Stage 1 toward the terminal rate. Longer windows are most useful for companies with high growth starting conditions or strong competitive advantages. This option stretches out the growth rate slowdown across 5, 10, or 15-year steps. A high-growth starting condition (exceeding a 25% initial growth rate) automatically applies a curve decay to simulate realistic, rapid market saturation.
i

Terminal growth rate

With long-term inflation between 3-5%, revenue must grow by that baseline to maintain flat real-world market share. This value sets the permanent terminal growth rate to factor into the valuation beyond the growth slowdown runway toward maturity.

3-Stage Financial Runway Horizon

🧠 Perpetuity Horizon Engine (Stage 3: Post-2035)

Terminal FCF Base$3.93B
Perpetuity TV Value$73.90B
Discounted TV (PV)$31.22B
TV Weighting %52.8%
⚠️
Financial Model Disclaimer & Risk Disclosure: This interactive scenario simulator is an educational sandbox provided strictly for informational and analytical research purposes. Core historical financial statements and consensus estimates are sourced directly via Financial Modeling Prep (FMP). All downstream outputs are entirely deterministic, hypothetical projections generated by combining automated mathematical formulas (including linear interpolation and Gaussian bell-curve decay models) with user-selected variables and third-party financial data inputs. Users assume all liability for trading decisions executed based on these sandbox calculations.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 AFLAC INC (AFL) — Investment Overview

🧩 Business Model Overview

Aflac is a specialized life and health insurer that monetizes long-duration insurance contracts. Policies are typically sold through established distribution channels that support policyholder enrollment and ongoing premium collection (including payroll-style mechanisms in Japan and payroll/benefits-related routes in the U.S.). The company collects premiums on a recurring basis, holds statutory reserves to fund future claims, and earns investment income on the capital backing those reserves. Profitability depends on underwriting discipline (pricing adequacy and risk selection), disciplined claims management, and prudent investment/asset-liability management.

💰 Revenue Streams & Monetisation Model

The core revenue stream is premium income from life/health insurance products, which is structurally recurring given the multi-year nature of coverage. Investment income on the invested assets backing reserves and surplus is a secondary but important earnings driver. Margins are influenced by:

  • Underwriting profit: the relationship between earned premiums and claim experience (morbidity/lapse behavior, policy utilization, and expenses).
  • Investment spread: returns earned on the portfolio versus the cost of policy liabilities, with significant sensitivity to interest rates and credit conditions.
  • Expense discipline: maintaining efficient acquisition and administration relative to policy count and premium density.

Overall, the monetization model is less “transactional” than in most sectors; it is driven by sustained premium retention, prudent reserving, and steady investment income with an emphasis on capital strength.

🧠 Competitive Advantages & Market Positioning

Aflac’s moat is best characterized as a regulatory and operational barrier plus policyholder switching friction (a form of switching costs), reinforced by an embedded distribution footprint. While insurance is highly regulated, the durable advantage comes from translating that regulation into operational execution—pricing, reserving, claims management, and capital adequacy—at scale.

  • Switching costs / policy inertia: Insurance is typically not “switchable” in a frictionless way. Surrendering coverage, reassignment of benefits, and underwriting/qualification frictions create policyholder inertia, supporting renewal-like behavior and helping stabilize premium flows.
  • Regulatory moat & capital discipline: Solvency and reserve requirements limit competitors’ ability to expand rapidly without credibility in actuarial pricing and capital sufficiency. Strong reserving culture reduces the risk of adverse reserve development.
  • Distribution know-how in differentiated niches: Aflac’s historical focus on supplemental insurance products supports deep expertise in product design and distribution mechanics, making it harder for generalist insurers to replicate performance quickly.

Competitive benchmarking (primary peers):

  • Prudential Financial (U.S. life/health): Broad life and health portfolio with a different mix and distribution footprint; less concentrated in supplemental-like positioning that Aflac emphasizes.
  • MetLife: Diversified insurance platform where supplemental products compete alongside broader life/employee benefits offerings, often with different underwriting and expense structures.
  • Japanese major life insurers (e.g., Dai-ichi Life, Nippon Life): Large domestic players with strong distribution and extensive product catalogs; Aflac’s positioning differs through a supplemental focus and long-established workplace distribution relationships.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, growth is primarily a function of demographic and demand tailwinds for insurance protection, paired with execution in underwriting and capital allocation:

  • Demand for supplemental health coverage: Aging demographics and rising out-of-pocket costs support structural demand for coverage that complements primary health systems.
  • Retention and productivity improvements: Sustained policy persistence and expense optimization can compound earnings even without relying on aggressive premium discounting.
  • Capital strength enabling product breadth: Aflac’s ability to maintain solvency and credibility in reserve adequacy supports long-duration product offerings and continued market participation.
  • Investment discipline through cycles: Underwriting and asset-liability management can help preserve spread and reduce downside during credit stress or rate volatility.
  • Currency translation as a structural variable: For a company with material foreign operations, currency effects influence reported results; the underlying operational growth remains driven by policy sales, retention, and claims experience.

⚠ Risk Factors to Monitor

  • Interest rate and spread compression risk: Lower yields can pressure investment income and the spread earned on policy liabilities, affecting profitability and capital metrics.
  • Underwriting and reserving risk: Adverse mortality/morbidity trends, changing lapse behavior, or inaccurate reserving could lead to less-than-expected profitability.
  • Regulatory and solvency regime changes: Insurance regulatory requirements, product approval processes, and accounting/reserve frameworks can increase compliance costs or constrain product flexibility.
  • Credit quality and investment portfolio risk: Concentration in specific credit sectors, spread widening, and default rates can impair investment performance and capital.
  • Foreign exchange risk (Japan exposure): Earnings and capital translation effects can introduce volatility in reported results.
  • Distribution and competitive pricing pressure: Increased competition may pressure premiums or raise acquisition costs, challenging underwriting margins.

📊 Valuation & Market View

Insurers are typically valued on a combination of earnings power, book value/capital efficiency, and the sustainability of underwriting and investment returns. Common valuation frameworks include:

  • Price-to-book (or capital-related multiples): Reflects confidence in reserving adequacy and long-term ROE prospects.
  • EV/earnings or EV/EBITDA analogs: Less directly comparable than in industrials, but used to contextualize cash earnings capacity.
  • Embedded value / capital generation mindset: Markets often focus on the durability of statutory capital generation and dividend capacity.

Key valuation drivers are the perceived durability of underwriting profitability, evidence of disciplined reserving through cycles, and the sustainability of investment spreads under different rate/credit environments.

🔍 Investment Takeaway

Aflac’s investment case rests on a durable insurance operating model supported by regulatory barriers, policyholder inertia, and an execution-oriented underwriting/reserving culture. The company’s long-duration, premium-driven earnings profile and capital discipline can provide resilience across cycles, provided underwriting discipline and investment risk management remain intact.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for AFL.

gurufocus.com2026-06-03

AFL Fairly Valued by DCF at $110

On June 03, 2026, we present a detailed DCF analysis for Aflac Inc (AFL), a company that has shown a price performance of +11.8% over the past year. The current

prnewswire.com2026-06-01

Aflac Incorporated to Present at the Morgan Stanley U.S. Financials Conference

COLUMBUS, Ga., June 1, 2026 /PRNewswire/ -- Aflac Incorporated (NYSE: AFL) announced today that President of Aflac Incorporated and Aflac U.S. Virgil R.

zacks.com2026-05-29

Why Is Aflac (AFL) Down 0.9% Since Last Earnings Report?

Aflac (AFL) reported earnings 30 days ago. What's next for the stock?

gurufocus.com2026-05-28

AFL DCF Analysis: Intrinsic Value $110 vs Price $115

On May 28, 2026, we delve into the discounted cash flow (DCF) analysis for Aflac Inc (AFL), a company that has shown a price performance of +5.2% year-to-date a

seekingalpha.com2026-05-24

Future Dividend Kings - Part Two

This article highlights eight companies on track to achieve Dividend King status, requiring 50+ consecutive years of dividend increases. The companies featured are not expected to reach Dividend King status until at least 2032, but are progressing steadily. The series aims to spotlight recognizable businesses with strong dividend growth histories, supporting long-term income-focused investment strategies.

zacks.com2026-05-21

Aflac Raises 65.9B Yen in Japan Bond Market Amid Foreign Issuer Rush

AFL raises 65.9B Yen in Japan's bond market as foreign issuers flock to Yen debt and investor demand stays strong for higher yields.

zacks.com2026-05-19

5 Stocks to Watch From Prospering Accident & Health Insurance Industry

Accident and Health Insurance stocks like AFL, UNM, GL, TRUP and EIG are set to gain from rising underwriting exposure and accelerated digitalization. However, pricing pressure is a concern given rising medical costs and inflation.

zacks.com2026-05-14

Here's Why You Should Keep Holding Aflac in Your Portfolio

AFL is seeing strong sales growth in Japan and the U.S., improving Japan margins and a lower benefit ratio, though premium valuation pressure remains.

seekingalpha.com2026-05-06

Aflac: An Insurer To Buy After Impressive Q1 Results, Even As Valuation Rises

Aflac remains a Buy despite a Q1 earnings miss, supported by organic policy growth, proven dividend increases, and robust balance sheet strength. Growth catalysts include new policy sales, expanding Asian market presence, and niche segments like pet insurance, though revenue trends remain uneven. Margins and expense ratios are favorable, with A-level credit ratings and conservative leverage, but forward P/E multiples signal some overvaluation and more muted near-term upside.

zacks.com2026-05-01

Aflac Q1 Earnings Miss Estimates on Lower Investment Income

AFL misses Q1 estimates as lower investment income and FX pressure weigh on results, though U.S. sales strength and improved earnings partly offset the downside.

prnewswire.com2026-05-01

Aflac opens new South Portland office to support Maine Paid Family and Medical Leave Program

Company brings services closer to home for more than 500,000 workers COLUMBUS, Ga., May 1, 2026 /PRNewswire/ -- Working with the Maine Department of Labor and the state's Paid Family Medical Leave (PFML) Bureau, Aflac, the leading provider of supplemental health insurance in the U.S.1 and contracted administrator for the Maine PMFL program, announced the opening of a new office in South Portland, Maine.

youtube.com2026-04-30

Aflac CEO Dan Amos on building an American success story

Aflac CEO Dan Amos reflects on the company's rise from humble Southern roots to a $60 billion powerhouse — and the bold bet that defined his career: a “damn duck.”

seekingalpha.com2026-04-30

Aflac Incorporated (AFL) Q1 2026 Earnings Call Transcript

Aflac Incorporated (AFL) Q1 2026 Earnings Call Transcript

zacks.com2026-04-29

Aflac (AFL) Reports Q1 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Aflac (AFL) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

zacks.com2026-04-29

Aflac (AFL) Q1 Earnings and Revenues Miss Estimates

Aflac (AFL) came out with quarterly earnings of $1.75 per share, missing the Zacks Consensus Estimate of $1.8 per share. This compares to earnings of $1.66 per share a year ago.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"AFL reported Q1 2026 revenue of $4.315B and net income of $1.019B (EPS $1.99). Versus Q1 2025, revenue is up +25.0% (from $3.453B) and net income is up ~+34.0x (from $29M). QoQ, revenue declined -11.8% (from $4.896B in Q4 2025) while net income fell -26.1% (from $1.379B), indicating earnings volatility quarter-to-quarter. Profitability improved meaningfully YoY: net profit margin rose to 23.6% in Q1 2026 from 0.84% in Q1 2025. However, sequential margins contracted versus Q4 2025 (net margin 28.2%), consistent with the QoQ net income decline. Operating cash flow totaled $968M, translating into ~$1.89/share free cash flow, while dividends paid were $304M—supported by operating earnings and modest payout (payout ratio ~29.8% on the provided metrics). Share repurchases were limited in the quarter (net buybacks ~-$1B plus a small stock issuance), and overall cash decreased by ~$591M. On total shareholder returns, the stock is up +6.69% over the last year—positive but not a >20% momentum setup. With dividend yield ~0.54%, the near-term return mix is more valuation/earnings driven than income."

Revenue Growth

Neutral

YoY revenue increased +25.0% (Q1 2026 $4.315B vs Q1 2025 $3.453B), but QoQ revenue declined -11.8% (vs Q4 2025 $4.896B), suggesting normalization/volatility.

Profitability

Positive

Net income up ~+34.0x YoY (Q1 2025 $29M to Q1 2026 $1.019B). Net margin rose to 23.6% YoY (from 0.84%), but contracted QoQ vs 28.2% in Q4 2025.

Cash Flow Quality

Positive

Operating cash flow was $968M in Q1 2026, converting strongly into free cash flow (~$968M). Dividends were $304M with a moderate payout ratio (~29.8%), indicating dividend support, though buybacks were not the dominant use of cash.

Leverage & Balance Sheet

Neutral

Total assets were $120.3B in Q1 2026, slightly up vs $116.5B in Q4 2025. Equity increased to $22.4B from $29.5B QoQ (on the provided fields), while long-term debt remained low (~$7.75B) and leverage appears manageable for an insurer context.

Shareholder Returns

Fair

Dividend yield is ~0.54% (low) and buyback activity was limited; the stock price is up +6.69% over 1Y. Not enough momentum for a strong total return score.

Analyst Sentiment & Valuation

Positive

Current price ~$114.52 vs consensus target ~$111.2 implies modest upside/roughly fair valuation. Low absolute dividend yield keeps valuation sensitive to earnings quality.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

Aflac Q1 2026 showed solid headline profitability with adjusted EPS up 6.6% YoY to $1.77 (FX-excluding), supported by reserve remeasurement gains (+$82M; $23M above plan). Japan delivered strong sales momentum (+25.5%) led by Onsen Tallett and Miraito, and improved profitability with pretax margin up 320 bps to 35% and benefit ratio down 290 bps to 62.9%—yet underlying earned premiums still declined (−1.3% ex major items). Management reaffirmed a Japan benefit ratio outlook of 60%–63% but framed the earned premium path as lagging, expecting underlying growth of roughly −1% to −2% for the full year until enough sales offset predictable lapsation (~JPY 90B). In the U.S., premiums rose (+3.5%) and persistency held at 79.3%, but expenses rose (+70 bps) and reserve impacts were above plan (+230 bps benefit ratio impact). Capital deployment remained aggressive ($1.0B repurchase; $315M dividends) with liquidity and capital ratios strong.

AI IconGrowth Catalysts

  • Japan: sales up 25.5% YoY driven largely by newest medical product Onsen Tallett and latest cancer insurance product Miraito
  • Japan: continued emphasis on third-sector protection to new/younger customers via first-sector product (name partially redacted)
  • Japan: distribution channel breadth—agencies, alliance partners, and banks all generated sales increases
  • U.S.: sales up 2.9% YoY with momentum in group voluntary products
  • U.S.: strong premium persistency 79.3% and net earned premium up 3.5%

Business Development

  • Effective March 31, 2026: Aflac Re Bermuda assumed a block of whole life annuities from Japan Post Insurance (immaterial to AFL Inc. financials but a strategic reinsurance milestone to expand the Japan reinsurance franchise)
  • Q1 2026: completed a first external-party Japan reinsurance transaction (size described as small vs enterprise); discussed as a step in the reinsurance evolution

AI IconFinancial Highlights

  • Reported net earnings per diluted share $1.98; adjusted EPS $1.75
  • Adjusted EPS increased 6.6% YoY to $1.77 excluding foreign currency effects
  • Remeasurement gains on reserves: $82M total; $23M (~$0.04 EPS) above plan reducing benefits
  • Variable investment income: $14M (~$0.02 EPS) below long-term return expectations
  • Adjusted book value per share (excluding FX remeasurement): +0.2%; adjusted ROE: 12.8% (16.4% excluding FX remeasurement)
  • Japan: net earned premiums declined 3.8% in yen terms; underlying earned premiums (ex reinsurance, paid-up policies, deferred profit liability) declined 1.3%
  • Japan benefit ratio 62.9% down 290 bps YoY; estimated reserve remeasurement impact ~70 bps vs plan
  • Japan expense ratio 19.5% down 10 bps YoY; pretax margin 35% up 320 bps YoY
  • U.S.: net term premiums +3.5%; total benefit ratio 47.2% (down 50 bps YoY) driven by favorable incurred claims for individual voluntary benefits and group disability
  • U.S. benefit ratio reserve remeasurement impact estimated ~230 bps (about 80 bps above plan)
  • U.S. expense ratio 38.3% up 70 bps YoY due to higher DAC amortization/commissions and timing of advertising/investment spend
  • Corporate & Other: breakeven pretax adjusted earnings; down from $43M gain last year, driven by lower adjusted net investment income, higher interest expense/operating costs, and runoff impacts from closed blocks
  • Tax credit investments: GAAP net investment income impact -$5M in the quarter with offsetting credit to tax line; noted no benefit in first-quarter earnings from tax credits
  • Investments/credit: $19M charge-offs on loan portfolio; $24M real estate owned impairments (commercial real estate depressed valuations); no foreclosures in period

AI IconCapital Funding

  • Returned $1.3B to shareholders in Q1 via share repurchases + dividends ($1.0B repurchased; $315M dividends)
  • Unencumbered liquidity: $3.4B (up $2.4B above minimum $1B at quarter end)
  • Adjusted leverage: 21.2% (within 20%–25% target range; impacted by yen-dollar moves due to ~65% of debt in yen)
  • Estimated regulatory ESR: 227%; ESR with USP: 243%; combined RBC approximately 560%

AI IconStrategy & Ops

  • Japan: marketing and sales transformation remains the major initiative; sales momentum attributed to dedicated leadership and cross-functional marketing/sales execution
  • Japan: simultaneously selling multiple medical/cancer/related products through a system designed to run concurrently (including cancer reinsurance Miraito, medical insurance, and other medical product—name partially redacted)
  • U.S.: focus on expense management to sustain pretax margins; expense ratio pressured by DAC amortization and commissions and timing of advertising and investment spend
  • U.S. agent growth: maintaining recruiting pipeline target; new agent conversion rate 16%, productivity ~8%, and 'new agent success' metric up 8% (agent reaching $25k in first 3 months and adding 3 new accounts)
  • Capital deployment approach: flexible/tactical balance sheet management; reinsurance used as add-on strategy to enhance earnings power and liquidity over time

AI IconMarket Outlook

  • Japan benefit ratio outlook: reaffirmed full-year range of 60% to 63%
  • Japan underlying earned premium outlook: expecting approximately -1% to -2% underlying earned premium for full year (hovering range) with line of sight to move toward flat and growth over time
  • Japan cancer/medical sales expectations: 2026 sales expected to be equivalent to 2025
  • Corporate & Other: management expects slightly negative pretax earnings in Q2 based on current volumes/rates and reinsurance runoff blocks

AI IconRisks & Headwinds

  • Japan: lapses and reissue on cancer insurance uptick; persistency down but still strong at 92.8% (risk to premium economics despite offsetting dynamics)
  • Japan: reserve remeasurement gains contributed positively to benefit ratio; underlying earned premiums still down (−1.3% ex reinsurance/paid-up/DP liability), indicating economic growth not yet showing through
  • Japan/U.S.: variable investment income below long-term expectations by $14M (~$0.02 EPS) and JPY/USD impacts on ESR/leverage
  • U.S.: expense ratio up 70 bps YoY from DAC amortization/commissions and timing of spend
  • Corporate & Other: earnings power swings driven by short-term rate path affecting net investment income on holdco cash and decay of runoff reinsurance blocks (~8% per year)
  • Investment/credit: $19M loan charge-offs and $24M real estate owned impairments reflect ongoing credit/CRE pressure
  • U.S. regulatory headline risk: state regulator forcing rate cuts mentioned in Q&A; management stated no additional material pressure observed

Q&A: Analyst Interest

  • Japan reinsurance economics & earnings timing: Management said the external Japan reinsurance transaction had relatively small capital impacts and initially pressured Japan earnings by mid-single-digit U.S. dollars (in millions). They expect negative earnings impact for the next couple of quarters, trending toward zero as policies reach paid-up status.
  • Japan benefit ratio bridge to full-year 60%–63%: Management cited drivers including lower net premium ratio set in Q3 2025, lapse/mix differences (less old-age cancer and more recently issued policy lapsation), and continued favorable trends. They emphasized an assumption unlock in Q3 to update net premium ratio inputs.
  • Japan earned premium inflection requirements: Management explained earned premium growth hinges on the sales level needed to offset predictable lapsation around JPY 90B. They implied that without reaching that sales magnitude, underlying earned premium stays roughly -1% to -2%, with a line of sight to flat and eventual growth as execution continues.

Sentiment: MIXED

Note: This summary was synthesized by AI from the AFL Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for AFL.

SEC EDGAR Live Feed
No recent 10-K available.
No recent 10-Q available.
Loading financial data and tables...
📁

SEC Filings (AFL)

© 2026 Stock Market Info — Aflac Incorporated (AFL) Financial Profile